GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » Buyback Yield %

TWi Biotechnology (ROCO:6610) Buyback Yield % : 0.00 (As of Jan. 18, 2025)


View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

TWi Biotechnology's current buyback yield was 0.00%.


TWi Biotechnology Buyback Yield % Historical Data

The historical data trend for TWi Biotechnology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology Buyback Yield % Chart

TWi Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -24.50

TWi Biotechnology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TWi Biotechnology's Buyback Yield %

For the Biotechnology subindustry, TWi Biotechnology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TWi Biotechnology's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TWi Biotechnology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where TWi Biotechnology's Buyback Yield % falls into.



TWi Biotechnology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

TWi Biotechnology's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 300) / 1224.73188
=-24.50%

TWi Biotechnology's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 2 / 1305.97606
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Jun. 2024) data.


TWi Biotechnology Buyback Yield % Related Terms

Thank you for viewing the detailed overview of TWi Biotechnology's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


TWi Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology Headlines

No Headlines